PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation
Your view on PRCT
Overview
What the company does, where it operates, and who runs it.
About PROCEPT BioRobotics Corporation
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Larry L. Wood
- Headquarters
- 900 Island Drive, San Jose, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Larry L. Wood
- Headquarters
- 900 Island Drive, San Jose, CA, US
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PROCEPT BioRobotics Corporation, and the rating behind it. PRCT last traded at $19.83; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PROCEPT BioRobotics Corporation. Starting points for PROCEPT BioRobotics Corporation: EPS -$1.94, beta 0.92 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PROCEPT BioRobotics Corporation. PROCEPT BioRobotics Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PROCEPT BioRobotics Corporation. Trailing twelve-month EPS for PROCEPT BioRobotics Corporation stands at -$1.94. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PROCEPT BioRobotics Corporation. PROCEPT BioRobotics Corporation has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PROCEPT BioRobotics Corporation valued side by side against its closest peers. PROCEPT BioRobotics Corporation is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PROCEPT BioRobotics Corporation, and how their positions are changing. At a $1.13B market value, institutional positions materially move PROCEPT BioRobotics Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PROCEPT BioRobotics Corporation executives and directors. Shares of PROCEPT BioRobotics Corporation have traded between $28.28 and $100.89 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PROCEPT BioRobotics Corporation. PROCEPT BioRobotics Corporation is a $1.13B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PROCEPT BioRobotics Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PROCEPT BioRobotics Corporation. Coverage tracks PROCEPT BioRobotics Corporation within Medical - Devices (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.